Skip to content
Search

Latest Stories

Second December price concessions

The Pharmaceutical Services Negotiating Committee has announced that the Department of Health and Social Care (DHSC) has granted further price concessions for the month of December 2021.

Here are the items in the list:


DrugPack sizePrice Concession
Celecoxib 100mg capsules60£2.71
Celecoxib 200mg capsules30£1.77
Cinnarizine 15mg tablets84£3.90
Clomipramine 10mg capsules28£2.32
Clomipramine 25mg capsules28£4.76
Clomipramine 50mg capsules28£7.90
Fenofibrate micronised 160mg tablets28£5.31
Fludrocortisone 100microgram tablets30£12.56
Losartan 100mg / Hydrochlorothiazide 25mg tablets28£2.98
Losartan 100mg tablets28£3.84
Losartan 25mg tablets28£2.64
Losartan 50mg / Hydrochlorothiazide 12.5mg tablets28£3.35
Losartan 50mg tablets28£2.70
Metformin 500mg/5ml oral solution sugar free150£40.00
Nortriptyline 10mg tablets100£1.99
Rivastigmine 3mg capsules28£3.99
Ropinirole 250microgram tablets12£3.25
Sulfasalazine 500mg gastro-resistant tablets112£31.99
Topiramate 25mg tablets60£2.89
Trazodone 100mg capsules56£3.52
Warfarin 500microgram tablets28£1.62

DHSC previously (15/12/2021) granted the following list of price concessions:

DrugPack sizePrice Concession
Amisulpride 50mg tablets60£2.99
Co-dydramol 10mg/500mg tablets30£2.10
Co-dydramol 10mg/500mg tablets100£6.99
Donepezil 1mg/ml oral solution sugar free150£81.23
Enalapril 10mg tablets28£5.21
Enalapril 5mg tablets28£5.87
Lamotrigine 5mg dispersible tablets sugar free28£8.50
Lansoprazole 30mg orodispersible tablets28£5.15
Lercanidipine 20mg tablets28£2.80
Loratadine 5mg/5ml oral solution100£5.85
Methocarbamol 750mg tablets100£14.89
Mirtazapine 15mg/ml oral solution sugar free66£97.89
Naftidrofuryl 100mg capsules84£7.90
Omeprazole 10mg/5ml oral suspension sugar free75£106.46
Omeprazole 20mg/5ml oral suspension sugar free75£206.00
Orlistat 120mg capsules84£23.07
Orphenadrine 50mg/5ml oral solution sugar free150£87.09
Pioglitazone 30mg tablets28£1.89
Pioglitazone 45mg tablets28£2.48
Prednisolone 5mg soluble tablets30£11.83
Procyclidine 2.5mg/5ml oral solution sugar free150£37.39
Procyclidine 5mg/5ml oral solution sugar free150£55.61
Promazine 25mg/5ml oral solution150£60.19
Promazine 50mg/5ml oral solution150£75.36
Quetiapine 20mg/ml oral suspension sugar free150£166.31
Ramipril 2.5mg/5ml oral solution sugar free150£164.12
Ropinirole 1mg tablets84£49.50
Simvastatin 20mg/5ml oral suspension sugar free150£173.89
Simvastatin 40mg/5ml oral suspension sugar free150£250.63
Sulfasalazine 250mg/5ml oral suspension sugar free500£94.22
Sulfasalazine 500mg tablets112£26.99
Tamoxifen 10mg/5ml oral solution sugar free150£74.52
Timolol 0.5% eye drops5£3.02
Tolbutamide 500mg tablets28£25.09
Tolterodine 1mg tablets56£3.46
Tolterodine 2mg tablets56£3.98
Topiramate 100mg tablets60£7.13
Topiramate 50mg tablets60£2.76
Trazodone 150mg tablets28£3.13
Trazodone 50mg capsules84£3.45
Ursodeoxycholic acid 250mg capsules60£9.95
Warfarin 1mg/ml oral suspension sugar free150£156.07

price concession only applies for the month in which it is granted. No additional prescription endorsement are required as the new price is automatically applied by the NHS BSA to all items submitted for payment in the same month for which a price concession is granted.

Contractors can find information and learn about the process involved on PSNC’s website.

More For You

GPhC should consider reduced fees for pharmacists non-practising practising, says RPS

RPS responds to GPhC consultation on draft changes to fees

gettyimages

RPS urges GPhC to reduce registration fees for non-practising pharmacists

The Royal Pharmaceutical Society (RPS) has called on the General Pharmaceutical Council (GPhC) to reduce annual registration fees for non-practising pharmacists — such as those on parental leave or with a long-term illness — in response to the regulator’s consultation on proposed changes to fees.

The GPhC is proposing a 6% increase in annual registration fees from September 2025 to cover the rising operational costs.

Keep ReadingShow less
Hay fever treatment: Dymista nasal spray now available in pharmacies without prescription

Hay fever affects one in four people in the UK

gettyimages

Hay fever treatment: First OTC combination nasal spray launched

For the first time, a double-action combination treatment for moderate to severe hay fever has been available over the counter across UK pharmacies, offering a new option for those sufferers who remain uncontrolled on a corticosteroid or antihistamine nasal spray.

Launched by global healthcare company Viatris, Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray— previously only available via prescription under the brand name Dymista — can be accessed without a GP visit.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less